NASDAQ:NERV - Minerva Neurosciences, Inc.
$7.03
 $-0.12
-1.68%
4:00PM EDT
2019-04-18
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  NERV     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 86   199. 07   233. 87  
42 stocks rank:  3. 45 K 1. 43 K 1. 06 K
# analyst opinions:  3. 00   14. 48   14. 09  

quick ratio:  24. 38   5. 29   1. 92  
current ratio:  24. 94   5. 64   2. 40  

target price low:  18. 00   84. 50   115. 74  
target price avg:  19. 00   110. 73   137. 39  
target price high:  20. 00   136. 41   157. 80  
1-yr high:  12. 55   114. 11   138. 85  
last close:  7. 03   87. 56   116. 78  
50-day avg:  7. 83   95. 43   123. 53  
200-day avg:  8. 63   94. 13   121. 20  
1-yr low:  6. 10   72. 67   98. 41  
volume:  81. 23 K 2. 43 M 4. 85 M
50-day avg volume:  129. 89 K 2. 72 M 4. 97 M
200-day avg volume:  166. 90 K 2. 90 M 4. 58 M

1-day return:  -1. 68 % -0. 40 % 0. 07 %
this week return:  -1. 13 % -5. 72 % -4. 11 %
12-wk return:  -0. 71 % 1. 78 % -0. 04 %
52-wk return:  7. 25 % 10. 81 % 14. 09 %

enterprise value (EV):  189. 47 M 51. 19 B 117. 96 B
market cap:  274. 36 M 43. 00 B 104. 52 B
EBITDA:  -51. 71 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -3. 66   4. 34   13. 27  
total debt:  0. 00   12. 22 B 16. 66 B
net income (common):  -50. 17 M 2. 20 B 4. 21 B

shares outstanding:  39. 03 M 570. 91 M 1. 24 B
shares:  37. 48 M 571. 02 M 1. 23 B
shares short:  1. 84 M 9. 93 M 16. 79 M
shares short prior month:  1. 46 M 9. 96 M 16. 58 M
short ratio:  12. 64   5. 31   3. 30  
short % of float:  9. 13 % 5. 81 % 2. 61 %
total cash/share:  2. 25   11. 13   9. 30  
total cash:  88. 00 M 6. 70 B 7. 10 B
free cash flow:  -24. 07 M 3. 58 B 4. 74 B
operating cash flow:  -41. 94 M 4. 14 B 6. 32 B

book value:  2. 32   12. 76   26. 84  
price/book:  3. 03   3. 08   -1. 74  
operating margins:  0. 00 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  0. 00 % 37. 02 % 55. 68 %

1-yr max volatility:  13. 85 % --- ---
1-yr mean volatility:  0. 05 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 29   2. 39   4. 08  
forward EPS:  -1. 50   3. 97   7. 14  
P/E:  -5. 44   13. 59   22. 83  
forward P/E:  -4. 74   -20. 05   14. 49  
PE/G:  0. 36   -1. 46   1. 68  
growth:  -15. 01 % 126. 81 % 29. 29 %
earnings high:  -0. 35   1. 02   1. 63  
earnings avg:  -0. 35   0. 76   1. 51  
earnings low:  -0. 36   0. 47   1. 39  
revenue high:  -0. 00   2. 68 B 10. 71 B
revenue avg:  -0. 00   2. 59 B 10. 49 B
revenue low:  -0. 00   2. 49 B 10. 25 B
return on assets:  -20. 03 % -2. 80 % 5. 29 %
return on equity:  -45. 23 % -18. 52 % 7. 38 %

beta (1yr vs S&P500):  1. 36   1. 24   0. 93  
sharpe (1yr):  0. 21   0. 29   0. 60  

held % insiders:  3. 79 % 6. 38 % 3. 38 %
held % institutions:  81. 12 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : NERV
.    + 1.358 =         1.358 :: INITIAL WEIGHT
.   + 45.175 =        46.533 :: spline projection addition
.    x 1.432 =        66.636 :: industry recommendation factor
.    x 0.998 =        66.503 :: return on assets factor
.    x 0.995 =        66.202 :: return on equity factor
.    x 4.289 =       283.944 :: current ratio factor
.    x 1.021 =       289.953 :: quick ratio factor
.    x 1.039 =       301.204 :: short ratio factor
.     x 2.03 =       611.543 :: price-to-book factor
.    x 2.078 =      1271.088 :: P/E weight
.    x 1.289 =      1638.451 :: PE/G factor
.     x 1.42 =      2326.894 :: beta factor
.    x 0.215 =        499.89 :: sharpe factor
.    x 2.446 =       1222.64 :: target low factor
.    x 1.435 =      1754.438 :: target mean factor
.    x 1.136 =      1992.742 :: target high factor
.    x 1.312 =      2613.776 :: industry 2-weeks return factor
.    x 0.938 =      2452.111 :: "drift" penalty 1 days ago
.    x 0.986 =      2418.012 :: "drift" penalty 2 days ago
.    x 0.898 =      2172.545 :: overall "drift" factor
.    x 0.862 =      1871.731 :: largest single-day jump factor
.    x 0.099 =       184.407 :: low price factor
.      x 1.0 =       184.377 :: factor hist industry gain for week 15
.   cubeRoot =         5.692 :: reduced to standardize
.   - 20.079 =          0.86 :: add/subtract for performance
.                       0.86 :: FINAL WEIGHT for NASDAQ:NERV


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org